Usmani, Omar S. http://orcid.org/0000-0002-4367-254X
Levy, Mark L. http://orcid.org/0000-0002-1807-3246
Funding for this research was provided by:
Chiesi Pharmaceuticals | Chiesi Foundation
Medical writing support was funded by Chiesi Limited and provided by Georgina Barr BSc (Hons) and Giovanni Ferrati PhD.
Article History
Received: 15 February 2023
Accepted: 14 June 2023
First Online: 1 July 2023
Competing interests
: O.S.U. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline; personal fees from Mapp Biopharmaceutical, Mundipharma, Sandoz and Takeda; grants from Edmond Pharma; and personal fees from Cipla, Covis Pharma, Menarini, Mereo BioPharma, Novartis and Orion. He is Chair of the UK Inhaler Group (UKIG) and a member of the Aerosol Drug Management Improvement Team (ADMIT) group (ExternalRef removed). M.L.L. has received consultancy fees from Aspire, AstraZeneca, Boehringer Ingelheim, Chiesi, Clement Clarke International, GlaxoSmithKline, Menarini, Novartis, NSHI, Orion, Respiri Ltd (Australia), Smart Respiratory Products Ltd and Teva Pharmaceuticals; speaker fees from AstraZeneca, Chiesi, NAPP, Novartis, NSHI, Orion and Teva Pharmaceuticals; honoraria from ADMIT Group—Consorzio Futuro in Ricerca (of University of Ferrara). M.L.L. is Editor Emeritus of <i>npj Primary Care Respiratory Medicine</i>, but was not involved in the journal’s review of, or decisions related to, this manuscript.